Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update
Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will announce its unaudited interim results for the six months ended 30 June
Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, notes the recent market speculation regarding possible fundraising.
Avacta Annual General Meeting and Shareholder Event Detailed Agenda
Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
A period of continued significant progress
Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
Avacta has expanded its footprint in the US. The listing could be next.